EIKN vs GLUE
EIKN: A clinical-stage biopharmaceutical company utilizing a proprietary technology platform to discover and develop a pipeline of novel therapeutic candidates. GLUE: Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its proprietary QuEEN discovery platform.
Side-by-side fundamentals
| Metric | EIKN | GLUE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.61 | $23.79 | |
| Market cap as of 2026-07-23 | $525M | $2.0B | |
| Net margin as of 2026-07-23 | n/a | -302.7% | |
| Operating margin as of 2026-07-23 | n/a | -345.2% | |
| ROE as of 2026-07-23 | -114.8% | -41.0% | GLUE higher |
| ROA as of 2026-07-23 | -54.5% | -25.9% | GLUE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -73.1% | |
| Beta as of 2026-07-23 | 2.06 | 1.49 | |
| 1-year return as of 2026-07-22 close | -33.9% | +305.3% | GLUE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.